The menopause drugs market is witnessing notable innovations and diverse market players. Pharmaceutical companies are introducing novel drug formulations, including hormone therapy alternatives, non-hormonal treatments, and personalized medicines, to address menopausal symptoms more effectively. Key market players such as Pfizer, Novartis, and Eli Lilly are actively involved in developing and marketing these products. Additionally, smaller companies and startups are focusing on herbal remedies and digital health solutions to cater to the growing demand for menopause management, reflecting the market's evolving landscape.
Access Full Report @ https://www.databridgemarketresearch.com/reports/argentina-menopause-drugs-market
Data Bridge Market Research analyses that the Argentina Menopause Drugs Market is growing with a CAGR of 4.6% in the forecast period of 2022 to 2029 and is expected to reach USD 50.80 million by 2029 from USD 35.65 million in 2021. The menopause drugs market is driven by the demand for efficient management of bothersome symptoms such as hot flashes and mood swings. Women seek relief through pharmaceutical solutions, propelling market growth.
Key Findings of the Study
Regulatory support is expected to drive the market's growth rate
Supportive regulations and guidelines for menopause treatment play a vital role in ensuring the safety and efficacy of therapies. Regulatory bodies provide clear directives for drug approval and usage, fostering trust among healthcare providers and patients. These regulations help in the development of well-researched and tested menopause treatments, offering a reliable framework for pharmaceutical companies to bring innovative therapies to market while assuring patients of their safety and effectiveness.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Stages (Postmenopause, Perimenopause and Menopause), Type (Non-Hormonal Therapy and Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Dyspareunia, Osteoporosis, Joint Pain, Depression, Weight Gain and Others), Dosage Form (Tablet, Cream, Patch/Film, Rings, Gel, Injection Shot, Spray and Others), Route of Administration (Oral, Parenteral, Transdermal, Vaginal and Others), End User (Hospitals, Clinic Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)
|
|
Market Players Covered
|
Laboratorios Bagó S.A. (Argentina), Química Montpellier SA (Argentina), GADOR S.A. (Argentina), Laboratorio Elea Phoenix S.A. (Argentina), ROEMMERS SAICF (Argentina), ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (Brazil), Abbott (U.S.), Laboratorios Bernabó (Argentina), GlaxoSmithKline plc (United Kingdom), TEMIS LOSTALO (Argentina), Novartis AG (Switzerland), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), Allergan (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Bayer AG (Germany)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Argentina menopause drugs market is categorized into seven segments: stages, type, menopause symptoms, dosage forms, route of administration, end user and distribution channel.
- On the basis of stages, the Argentina menopause drugs market is segmented into postmenopause, perimenopause, and menopause. In 2022, it is anticipated that the postmenopause segment will take the lead in the Argentina menopause drugs market, primarily attributed to the considerable therapeutic efficacy of the chosen medication.
- On the basis of type, the Argentina menopause drugs market is segmented into non-hormonal therapy and hormonal therapy. In 2022, the Argentina menopause drugs market is poised to be led by the non-hormonal therapy segment. This shift is driven by the segment's potential for therapeutic benefits, the convenience of supplement administration, and the growing awareness among women regarding post-menopausal concerns.
- On the basis of menopause symptoms, the Argentina menopause drugs market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, joint pain, depression, weight gain and others. In 2022, the Argentina menopause drugs market is anticipated to be led by the vasomotor segment. This projection is attributed to the heightened demand for addressing issues such as hot flashes and vaginal dryness, which stem from vasomotor symptoms. It's also driven by market players' investments in research and development (R&D) and the concurrent rise in disposable income among the target demographic.
- On the basis of dosage form, the Argentina menopause drugs market is segmented into tablet, cream, patch/film, rings, gel, injection shot, spray, and others. In 2022, the Argentina menopause drugs market is poised to be led by the tablets segment. This trend is a result of the growing preference for oral administration among middle-aged women in Argentina, specifically for addressing hot flashes and dyspareunia. The shift is further fueled by increased awareness of the onset of menopausal symptoms and a surge in the retail sales of tablets in this category.
- On the basis of route of administration, the Argentina menopause drugs market is segmented into oral, parenteral, transdermal, vaginal, and others. In 2022, the Argentina menopause drugs market is anticipated to be primarily led by the oral segment. This dominance stems from the fact that a significant portion of the drugs offered by companies and favored by consumers are administered orally.
In 2022, the oral segment of the route of administration segment is expected to dominate the Argentina menopause drugs market during the forecast period of 2022-2029
In 2022, the oral segment of the route of administration segment is expected to dominate the Argentina menopause drugs market. This dominance stems from the fact that a significant portion of the drugs offered by companies and favored by consumers are administered orally.
- On the basis of end user, the Argentina menopause drugs market is segmented into hospitals, clinics, home healthcare, and others. In 2022, the hospitals segment of the end user segment is expected to dominate the Argentina menopause drugs market. This leadership is driven by increased research and development efforts focused on exosomes, government funding support for menopause drug development in Argentina.
In 2022, the hospitals segment of the end user segment is expected to dominate the Argentina menopause drugs market during the forecast period of 2022-2029
In 2022, the hospitals segment of the end user segment is expected to dominate the Argentina menopause drugs market. This leadership is driven by increased research and development efforts focused on exosomes, government funding support for menopause drug development in Argentina, and the essential role played by gynaecologists in providing accurate prescriptions and guidance for the correct use of both hormonal and non-hormonal therapies, consolidating this segment's dominance in the market.
- On the basis of distribution channel, the Argentina menopause drugs market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. In 2022, it is foreseen that the Argentina menopause drugs market will be primarily led by the hospital pharmacy segment. This leadership position is attributed to the heightened engagement with certified prescribers and healthcare professionals, particularly regarding the usage of anti-depressant medications. Additionally, the assurance of guaranteed payment further bolsters this segment's dominance in the market.
Major Players
Data Bridge Market Research recognizes the following companies as the Argentina menopause drugs market players in Argentina menopause drugs market are Laboratorios Bagó S.A. (Argentina), Química Montpellier SA (Argentina), GADOR S.A. (Argentina), Laboratorio Elea Phoenix S.A. (Argentina), ROEMMERS SAICF (Argentina), ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (Brazil).
Market Development
- In October 2020, Pfizer Inc. revealed that the United States Food and Drug Administration (FDA) had granted approval for DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets. This innovative therapy was designed for women with a uterus and intended for the treatment of moderate-to-severe vasomotor symptoms linked to menopause, as well as the prevention of postmenopausal osteoporosis. This regulatory milestone significantly expanded Pfizer's product portfolio, contributing to the company's growth.
For more detailed information about the Argentina menopause drugs market report, click here – https://www.databridgemarketresearch.com/reports/argentina-menopause-drugs-market
